Clinical Data and Biospecimens are available to researchers

We are pleased to announce another important milestone in PPMI: the launch of the PPMI Data and Biospecimen Request process.

One of the aims of PPMI is to provide easy and open web-based access to data, information, and biosamples acquired from the PD and age and gender matched healthy control subjects who are participating to the research community. The data is made available with the overarching goal of fostering collaboration and data sharing to promote the rapid identification and validation of PD biomarkers, to identify markers of PD onset and progression, and ultimately aid in the development of disease-modifying therapies for Parkinson patients.

To date, baseline clinical data from at least 50 enrolled individuals can be downloaded. While we recognize that the current data set is limited and that it is premature to draw conclusions regarding the PPMI cohort at present, we remain very excited to be able to share the PPMI data scaffold and biomarker request process. The data and the sample inventory will be constantly updated as new study participants are enrolled and the longitudinal study assessments are completed.

The PPMI database contains data from PD and healthy subjects acquired at all PPMI clinical sites. These data will include clinical (demographic, motor and non-motor, cognitive and neurobehavioral), imaging (DAT and MRI), and blood chemistry and hematology subject assessments and biospecimen inventories (serum, plasma, whole blood, CSF, DNA, RNA and urine).
Learn more about the PPMI data and to request access to the data.
Learn more about the specimen request process, the samples being collected in PPMI or to request access to the samples.

To review the study protocol, including the complete set of tests, assessments and specimens being collected in the study, click here.